OBJECTIVES: The feasibility of transcatheter aortic valve implantation (TAVI) in patients with a failing surgical aortic bioprosthesis has been reported from single centres. We present results from a multi-centre feasibility study in such patients followed for 1 year after TAVI.
INTRODUCTION
Transcatheter aortic valve implantation (TAVI), as a relatively new technology, has gained rapid acceptance worldwide for the treatment of symptomatic aortic stenosis in high surgical risk or inoperable patients [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . It has been shown to reduce mortality compared with medical therapy in inoperable patients and demonstrated similar survival outcomes compared with surgery in high-risk patients [10, 11] . In other indications, such as highrisk patients with degenerative or failing surgical aortic bioprostheses, further evidence for TAVI is required. The need for a less invasive treatment such as TAVI is greater in this already high-risk cohort because of the added inherent risks of repeat cardiac surgery of up to 15% higher than the index surgery [12, 13] . The feasibility of TAVI in these patients has been reported from single centres with encouraging results [14] [15] [16] [17] [18] [19] [20] [21] [22] . We present results from a multi-centre study with one of the largest series of such patients, followed for 1 year after TAVI with the CoreValve System (Medtronic CoreValve, Irvine, CA, USA).
MATERIALS AND METHODS

Study design and patient selection
This was a prospective multi-centre single-arm feasibility study. The objectives were to assess the effectiveness and safety of the 18-Fr CoreValve system within a failing aortic bioprosthesis during the immediate post-implantation period and up to 1 year after implantation. Within the study period, 18 eligible patients underwent TAVI in 3 experienced centres in Germany. Inclusion criteria were patients ≥75 years old with symptomatic failing bioprosthetic aortic valves (stenotic, regurgitant or mixed) and either a logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) ≥15% or one of the high-risk features listed in Table 1 . In addition, the inner diameter of the failing 12. Any acute neurological event or dysfunction occurred in the past 6 weeks before baseline or patient with severe senile dementia 13. Therapeutic invasive cardiac procedure, other than balloon aortic valvuloplasty, performed within 30 days prior to the study procedure or to be performed during or within 30 days after the study procedure 14. Currently, enrolled in this study or another investigational drug or device study CABG: coronary artery bypass grafting; EuroSCORE: European System for Cardiac Operative Risk Evaluation; FEV1: forced expiratory volume in first second.
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S.H. Ong et al. / European Journal of Cardio-Thoracic Surgery bioprosthesis (homograft or stented or stentless heterograft) had to be ≥19 and <26 mm as determined by Doppler echocardiography. The full lists of inclusion and exclusion criteria are listed in Table 1 . The clinical assessment and determination of a significant failing bioprosthesis were dependent on the respective institutions within the context of heart teams.
The study was approved by the respective institutional ethics committees and written informed consent was obtained from all patients.
Study endpoints
The primary endpoints were divided into safety and effectiveness categories. The primary safety endpoint was the composite major adverse events (MAEs) at 30 days including major adverse cardiac or cerebral events (MACCEs) consisting of cardiac death, documented Mobitz type 2 or complete atrioventricular block, neurological events and surgical aortic valve replacement; and other MAEs including non-cardiac death, structural or nonstructural prosthetic valve dysfunction, cardiac tamponade, cardiogenic shock, aortic dissection or perforation, major bleeding, peripheral embolic events and emergent revascularization procedures.
The primary effectiveness endpoints included technical and procedural success. Technical success was defined as the successful access of the failing bioprosthesis via a peripheral vessel with the delivery catheter, accurate deployment of the CoreValve across the failing bioprosthesis and successful removal of the intact delivery system. Procedural success was defined as adequate valve placement and function as determined by echocardiography at discharge or Day 10 post-procedure, whichever occurs first, and without composite MAE on discharge.
Secondary endpoints included the incidence of the composite MAEs at 6 months and 1-year post-implantation, patient functional status evaluated by the New York Heart Association (NYHA) functional class at 1, 6 and 12 months post-procedure, and valve performance (including valve surface area, transvalvular gradient and valve regurgitant grade) as measured by echocardiography at 1, 6 and 12 months post-procedure. In addition, the incidences of valve migration, paravalvular leak, valve endocarditis and surgical valve intervention were assessed. Patients' perceptions of their health status were evaluated by quality-of-life questionnaires at baseline and at 1, 6 and 12 months post-procedure. The EuroQOL (EuroQol Group) scales were used for this purpose. The two scales were the EQ-5D TM questionnaire and the visual analogue scale (VAS). The former reflects the patient's overall health state and has five descriptive dimensions: anxiety/depression, mobility, self-care, usual activities and pain/discomfort. The scale ranges from 0 to 1 (lowest to highest). The VAS is on a scale of 0-100 and the individual provides a quantitative measure of their current self-rated health status perception by marking the scale. Here, 0 means the worst imaginable health state and 100 is the best imaginable health state.
Study device and procedure
The transfemoral implantation of CoreValve has been described previously [2, 3] . In this study, the majority of implantations were done under local anaesthesia and conscious sedation. The use of general anaesthesia was dependent on operator discretion. Pre-closure preparation of the large femoral artery access with a percutaneous suture system was routinely performed. However, when necessary, a surgical femoral artery cut-down could be employed. We did not use the subclavian or transaortic route for any of the patients. A bolus dose of unfractionated heparin was given after the large femoral sheath insertion, as intra-procedural anticoagulation. There was no routine post-procedural anticoagulation. The CoreValve implantation was performed in the standard way as for native aortic stenosis except that preimplantation balloon aortic valvuloplasty under rapid pacing was not routinely performed. This was up to the operator's discretion. Post-implantation peak-to-peak aortic gradient measurement and visual estimation of aortic regurgitation (AR) on contrast aortography were performed for all patients. Figure 1 illustrates a typical implantation of the CoreValve in a failing surgical bioprosthesis.
Data management and statistical analysis
All MAEs in the first 30 days were adjudicated by an independent Clinical Events Committee. Clinical, fluoroscopic and echocardiographic assessments were performed at the implanting institutions.
Descriptive statistics, including means with standard deviations and frequency tables, were used to summarize the results. Survival and time-to-event analyses were performed using Kaplan-Meier survival analyses.
Medtronic CoreValve (Irvine, CA, USA) initiated and funded this study. An independent contract research organization was initially contracted to perform all data collection and monitoring activities, and later Medtronic assumed full study management and analysis responsibilities.
RESULTS
Patient characteristics
The mean age of patients was 79.1 ± 4.1 years with 33.3% women. All patients were symptomatic with 78% (14/18 patients) in NYHA functional Class III/IV. The mean logistic EuroSCORE was 34 ± 14%. The failed surgical bioprostheses were from 6 manufacturers with 10 patients having stented heterografts and the rest stentless heterografts. Of these, 5 (28%) were stenotic degeneration, 6 (33%) regurgitant and 7 (39%) mixed. The mean age of the surgical bioprostheses was 7 years with a range of 1-15.75 years. The baseline characteristics of the 18 patients are summarized in Table 2 .
Procedural and 30-day primary outcomes
The technical success of CoreValve implantation within a failing bioprosthesis was 94% (17/18 patients). The only technical failure was due to a deep implantation of the CoreValve resulting in severe AR and conversion to surgery. The mean procedural time was 89 ± 44 min. The smaller sized 26-mm CoreValve prosthesis was used in all but one patient who received the larger 29-mm valve. The patient implanted with the 29-mm CoreValve had a degenerated 27-mm Medtronic Intact surgical bioprosthesis.
The transfemoral route was used for all patients. Fully percutaneous procedures using access site pre-closure with a percutaneous suture system were performed for all but one who required a surgical cut-down of the femoral artery due to peripheral vascular disease. Pre-implantation aortic valvuloplasties were performed in nine patients and four patients required post-dilatation of the CoreValve prosthesis. There were two patients with AR of Grade ≥2 immediately post-implantation, both of whom eventually died (sudden cardiac death on Day 13 and multi-organ failure at 8 weeks). There was no reported AR >Grade 1 at the 6-and 12-month follow-up visits.
Procedural success, defined as adequate valve placement and function with freedom from the composite MAEs at discharge, was achieved in 9 (50%) patients. Apart from one patient with technical failure requiring conversion to surgery followed by stroke, seven other patients experienced MAEs during the in-hospital period including sudden cardiac death (n = 1), stroke (n = 1) resulting in death, major bleeding (n = 2) and infra-hisian atrioventricular block (n = 4). Multiple MAE complications occurred in three patients, whereas one patient had major bleeding and four patients had infra-hisian block as their only complication. The conduction blocks were largely transient and one patient (5.6%) eventually required a permanent pacemaker. The patient with major bleeding experienced bleeding from the femoral artery access site during the procedure and was treated with endovascular stenting. Apart from the one technical failure and seven patients with MAEs, one other patient did not meet the criteria for procedural success because this patient required two attempts before successful CoreValve implantation. In this patient, the first CoreValve was not in a satisfactory position before full release and was successfully removed from the patient intact while still attached to the delivery catheter. This was followed by successful deployment of a second CoreValve prosthesis.
The primary safety endpoint, which is the 30-day composite MAE including MACCE occurred in eight (44.4%) patients. The rate of MACCE at 30 days was 39% (seven patients). All-cause mortality occurred in two patients (11%) within 30 days. One patient had a sudden cardiac death on Day 13 post-procedure and the other died from a major stroke on the day of procedure. Of note, no structural dysfunction of the CoreValve or cardiac tamponade occurred and no emergent coronary revascularization was required.
One year and other secondary outcomes
Follow-up data were available for all patients up to 1 year postprocedure. At 1 year, the rate of death from any cause was 28% (five patients). Apart from the two deaths before 30 days, another patient died of multi-organ failure after 8 weeks and two others due to malignancies >6 months after TAVI. There were no new neurological events after 30 days. At 30 days, there was an increase in the mean aortic valve effective orifice area ADULT CARDIAC from 0.9 ± 0.3 to 1.5 ± 0.3 cm 2 and a reduction of the mean aortic gradient from 37 ± 14 to 17 ± 8 mmHg. These parameters were largely maintained up to 1 year with a negligible increase of 2 mmHg in the aortic gradient (Table 3) . There was an improvement of at least one NYHA functional class in 86.6 and 69.2% of patients at 30 days and 1 year post-TAVI, respectively. No surviving patient had deterioration in NYHA class. At the end of 1 year, only 23% of patients were in NYHA Class III and none in Class IV compared with 78% of patients in either NYHA Class III or IV before TAVI. Patients' perception of their health status also improved as gauged by the two quality-of-life scales. The EQ-5D
TM scale assessing overall mental and physical health state improved from the pre-TAVI baseline of 0.6 ± 0.3 to 0.8 ± 0.3 points (1.0 being the maximum). Similarly, the mean VAS improved from 49 ± 15 to 75 ± 10 points 1 year after TAVI.
No evidence of valve dysfunction or migration was seen at 1 year. There was no significant change in the left ventricular ejection function, cardiac output, left heart dimensions and pulmonary pressures at 1 year compared with baseline values.
We further stratified the outcomes into subgroups according to the baseline surgical bioprosthesis status in Table 4 , which include stenotic, regurgitant and mixed profiles. There appeared to be a higher rate of 30-day MACCEs in the stenotic-only group (n = 5) with all the deaths and neurological complications occurring in this subgroup. However, the numbers within each subgroup are too small to perform meaningful significance testing. Similarly, out of the five deaths at the end of 1 year, three came from this group. Figure 2a demonstrates the survival graph for the overall patients (72% survival at 1 year) as well as survival for the subgroups of surgical bioprosthesis pathology. Figure 2b presents the freedom from composite MAE in the same groups.
DISCUSSION
This is the largest series of TAVI with the CoreValve prosthesis in failing surgical bioprostheses and with the longest follow-up results. Previous reports ranged from case reports to case series of the so-called valve-in-valve TAVI using either the CoreValve prosthesis or the Edward Sapien (Edwards Lifesciences, Irvine, CA, USA) prosthesis [14] [15] [16] [17] [18] [19] [20] [21] [22] . Of note, the case series for CoreValve have been small, limited to numbers of less than 5 patients [15, 21] . However, there are larger case series of up to 16 patients for the Edward Sapien valve [19, 21, 22] . These mainly utilized the transapical route in contrast to the fully transfemoral approach used in our patients. Piazza et al. reported one of the largest series of valve-in-valve TAVI with a total of 20 patients, of whom 16 received the Sapien valve (15 were transapical), 3 received the CoreValve and 1 patient did not receive an implant. The immediate implantation success rate was 90% and the 30-day mortality was 15%. Of the three CoreValve implantations, one was unsuccessful, requiring surgery, while another required a second Sapien valve due to significant AR [21] . The other large series was reported by Webb et al., involving 10 patients who received the Sapien valve (9 via the transapical approach). Their first patient required a second Sapien valve, but all procedures were ultimately successful and they achieved no mortality at 30 days [22] . While the reported results for transapical valve-in-valve TAVI with the Sapien valve appear better than that of the CoreValve prosthesis, our results with the CoreValve prosthesis are relatively encouraging. In particular, our technical success rate of 94% is comparable to the best of reported results for TAVI in general, ranging from 91.2 to 98% [3, 5, 7, 8] . Similarly, the 30-day mortality rate of 11% is reasonable compared with a broad range of 5.4-14% reported with the CoreValve prosthesis [3, [6] [7] [8] [9] . Although the rate of composite MAEs of 44% was high, half of these were contributed to by patients (four patients, 22%) who had an AV block as their only complication. Eventually, only one of these four patients required a permanent pacemaker. It is important to note that this particular cohort of patients is at a relatively higher risk as evidenced by a high mean logistic EuroSCORE of 34%. The 1-year survival rate of 72% was contributed to by three deaths between 1 and 12months of the postprocedure period. However, two of these deaths were due to malignancies and were not related to the TAVI procedure. Having said this, surgical re-operative aortic valve replacement is still the treatment of choice in the majority of patients as it has shown good outcomes. Early mortality rate ranges from 3 to 7% [13] . Recent data showed a 30-day mortality of 6% [23] . However, this risk does increase with the age of patients operated upon, up to 12.6% for patients >70 years of age [13] . Thus, the outcome of TAVI may be reasonable in comparison to re-operation in a specific cohort of high-risk and elderly patients.
The main purpose of TAVI is not merely to prolong life but in fact to improve the quality of life. This becomes doubly important in this cohort of extremely high-risk patients who will likely be rejected for repeat surgery. The improvement in NYHA functional class after TAVI in the surviving patients was significant from 78% of patients in NYHA Class III/IV to 23% 1 year postprocedure. This improvement was already seen at the 1-month follow-up and was sustained up to 1 year. Furthermore, patients' subjective feeling of well-being also improved as assessed by the quality-of-life questionnaires. Sustained improvement up to 1 year after TAVI was also noted in the sustained increase in the aortic valve effective orifice area and the stable reduction in the mean aortic gradient. A point to note is that some amount of aortic gradient will remain after TAVI in a failed bioprosthesis [19, 21] , which is higher compared with the gradient after TAVI for native aortic valve stenoses [3, 6, 7] and is caused by the relative narrowing of the outflow tract by the suture ring of the surgical bioprosthesis. Post-TAVI monitoring should focus on its trend instead of absolute values. This phenomenon may also temper the enthusiasm of surgical bioprosthesis use in younger patients because although TAVI is feasible in the event of degeneration of the initial surgical valve, a second TAVI later for a degenerated TAVI prosthesis may not be possible due to an unacceptably high gradient after three layers of prostheses. From our experience, there appears to be potential technical benefits and challenges in performing TAVI in this particular cohort compared with the usual indication of degenerative stenotic native aortic valve. Firstly, the surgical bioprosthesis provides a visible reference for the aortic annular plane. This facilitates finding the optimal angiographic view before positioning and deploying the TAVI prosthesis, and reduces the amount of contrast medium used. Secondly, balloon valvuloplasty can be avoided in most cases, especially in patients without severe stenosis of the surgical bioprosthesis, reducing the risks inherent to valvuloplasty and rapid pacing. Thirdly, the circular nature of the surgical bioprosthesis may provide a better fixation and seal of the TAVI prosthesis, reducing the risk of AR and valve migration. This may be a reason for the low rate of AR seen in our series. However, patients with significant post-implantation AR may have poorer outcomes. Fourthly, the measurement of the aortic annulus becomes less important because the TAVI prosthesis size selection is dependent on the internal diameter of the surgical bioprosthesis. Finally, another benefit is the low rate of permanent pacemaker requirement. In our study, only one (5.6%) patient required a permanent pacemaker. This is markedly lower than the usual reported rates with the CoreValve prosthesis that ranged from 16% to as high as 39% [6, 8, 9] . In fact, two series of valve-in-valve TAVI with the Sapien valve reported no requirement for a permanent pacemaker [21, 22] . It has been suggested that the rigid surgical bioprosthesis limits the pressure on the ventricular septum and conduction system by the TAVI prosthesis. We postulate that the initial high rate of transient AV blocks (28%) seen in our cohort may be due to temporary oedema of the conduction system due to pre-or post-balloon dilatation and CoreValve deployment. However, full expansion of (22) 2 (40) 1 (17) 1 ( Technical success is successful access to the failed bioprosthesis, accurate deployment and intact removal of the delivery system. d Procedure success is a successful study procedure with freedom from composite MAE at discharge.
the self-expanding CoreValve may be limited by the surgical bioprosthesis allowing for recovery of the conduction abnormalities.
On the other hand, the suture ring of a small surgical bioprosthesis together with the relative oversizing and the funnel shape inflow part of the CoreValve prosthesis can cause a very strong tendency for a ventricular movement of the CoreValve prosthesis during implanting. Strong fixation of the CoreValve may render repositioning maneuvers such as the snare technique extremely difficult and potentially impossible. In such a case, a TAVI in the TAVI bail-out strategy has been performed by Piazza et al. But, despite good acute results, the patient died on Day 3 [21] . A smaller than the now available 26-mm CoreValve prosthesis would be desirable to overcome this technical issue and for the treatment of smaller failing aortic bioprostheses. Another possible complication is coronary occlusion suspected to be due to displaced surgical bioprosthetic leaflets or calcium after TAVI. Although not seen in our series, it has been reported after Sapien implantations [21, 24] . Hence, care should be taken to measure the distance between the surgical bioprosthesis and the coronary ostia and to determine the specific surgical valve dimensions, leaflet length and aortic root anatomy before proceeding with TAVI [24] .
In the sub-analysis according to the surgical bioprosthesis status before TAVI, we see a trend of increased adverse events in the stenotic-only group in particular death, neurological events, non-structural valve dysfunction and pacemaker requirement. Compared with a regurgitant bioprosthesis, the morphology of the stenotic surgical valve leaflets have greater resemblance to the calcific degeneration seen in native valves, and hence the increased risk of cerebral embolism, deep implantation and conduction system dysfunction.
The main limitation of our study is the small number of patients limiting statistical analysis. Nevertheless, this is the largest of such a series so far and it contributes to the growing evidence of the feasibility of TAVI in failing surgical bioprostheses.
In conclusion, our study showed that transfemoral TAVI with the CoreValve prosthesis is effective in high-risk patients with failing surgical aortic bioprostheses, whether due to stenosis, regurgitation or a mix of both. Benefits in terms of functional status and prosthesis performance were sustained through at least 1 year. In our cohort, the safety of this strategy is hampered by the occurrence of AV blocks. However, these were largely transient. A high complication rate was noted in the stenotic-only subgroup although the population was too small for meaningful interpretation. Further experience is required especially in this subgroup. Finally, TAVI in this cohort comes with a unique set of benefits and risks that should be taken into consideration before it is performed.
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APPENDIX. CONFERENCE DISCUSSION
Dr A. Bochenek (Katowice, Poland): I think it is a very important paper because it shows us that TAVI in a failing aortic valve prosthesis is possible, and is possible during the femoral and during the apical approach.
You have pointed out the limitation of this study, but this study, together with the previous study by Pasic from the Hetzer centre and the groups of Walther and Mohr, gives us more valid information about the early problems and longer term results.
In this study the technical success was 94%, but procedural success, defined as adequate valve placement and function on discharge from the hospital, was only 50%. The primary safety end point, including MACCE, was only 44%, early mortality 11%, one-year mortality, 28%.
First question. How many patients in your group were disqualified completely from surgery, and in how many patients did the surgeon have a role in the decision to disqualify the patient from surgery? I know that this is a very difficult group, and we are very happy that somebody is helping us to sort out this problem in our department, but the results are not good. In a good centre, the results, even with a difficult operation, can be better. How many patients were completely disqualified from surgery?
The other question is the approach. We know from the other study that the apical approach maybe is easier because the transapical approach is independent of the degree of patient pericardial disease and advancing the wire antegrade is easy, repeatable, and simple. How many patients were disqualified because of a very calcified aortic and iliac vessel in this group?
One more question about the valvuloplasty. What was the indication for valvuloplasty before the deployment of this valve?
Dr Mueller: I fully agree that the results are not perfect. There is need for improvement. The main thing I think is that the positioning of the CoreValve in a small bioprosthetic valve is cumbersome, because there is a very strong tendency to move inwards, and in many of these what we did find were negative results due to this fact. Perhaps the development of a smaller CoreValve could overcome this problem. The smaller CoreValve will come. In our centre, we decided if we do have very small surgical valves implanted, we prefer an Edwards prosthesis implanted, and we do have better results then.
We presented and discussed all of our patients with our cardiovascular team. All but one were not accepted for surgery by them. But this was a study and we could treat them.
Regarding your other question, in the first two patients with pure aortic, or stenosis of the bioprosthetic valve, we did a valvuloplasty because we were used to it, and in the next, we avoided it.
Dr F. Mohr (Leipzig, Germany): I think you already made a very good point, that a balloon-expandable valve of the same size, like the bioprosthesis most likely, works much better than a self-expanding type design in our hands also, and there should be a clear message here.
And I also want to point to a paper, which I do think is important, concerning the structure and leaf pathology of some valve types which have a very high profile, like, for example, the Mitroflow and/or the Trifectam, implanted in a small root, are contraindications for a kind of TAVI, because it is very likely that by dilating the frame a little bit you may occlude the coronary ostia. So these are things we should consider in defining which is the optimal type of TAVI route. I think transapical is a very good one since you can approach the mitral as well, but also I think you made the point that the self-expanding type is not the optimal design. Aortic regurgitation with a balloon-expandable type valve does not occur in the frame, and I think this is advantageous. But, still, we need to look at the valves we have implanted at the very beginning, because from that experience you can decide whether you can or cannot do it. Transcatheter aortic valve implantation (TAVI) has become a reliable treatment modality for aortic valve stenosis. More than 10 years after the first implantation, it is still debatable which patients may benefit from TAVI compared with surgical aortic valve replacement (SAVR) although the Partner A study [1] described a well-defined patient population as optimal candidates for TAVI. Evidence for further indications is still needed.
Aortic valve re-operation may carry a higher perioperative risk compared with first-time SAVR because patients are older but technically speaking, redo-SAVR is not extremely demanding [2] . Transcatheter aortic valve-in-valve implantation (ViV TAVI) might
